Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
WALTHAM, Mass., Nov. 08, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in the Jefferies 2017 London Healthcare Conference on Wednesday, November 15th at 2:40 p.m. GMT (9:40 a.m. ET).
To access the live webcast, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of the event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
